Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 10.45
- Piotroski Score 3.00
- Grade Buy
- Symbol (COGT)
- Company Cogent Biosciences, Inc.
- Price $11.74
- Changes Percentage (-1.09%)
- Change -$0.13
- Day Low $11.72
- Day High $11.98
- Year High $12.61
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/11/2024
- Fiscal Year End N/A
- Average Stock Price Target $18.50
- High Stock Price Target $24.00
- Low Stock Price Target $15.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.49
- Trailing P/E Ratio -3.37
- Forward P/E Ratio -3.37
- P/E Growth -3.37
- Net Income $-192,410,000
Income Statement
Quarterly
Annual
Latest News of COGT
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation
Owning shares of unprofitable companies can be profitable, like Salesforce.com. However, many such companies go bankrupt due to cash burn. Analyzing Cogent Biosciences' cash runway and burn rate shows...
By Yahoo! Finance | 2 weeks ago
